
Antiverse and GlobalBio Inc. extend collaboration
AI specialist Antiverse Ltd (Cardiff, UK) and antobody engeeniering expert GlobalBio, Inc. (New York, USA) will be extending their collaboration to...

Valnevas Lyme vaccine trial complets recruitment
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. announced that they have completed enrollment in the Vaccine Against Lyme for Outdoor...

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

Aboleris Pharma bags €27.3m in Series A Financing
AbolerIS Pharma SA’s financing was led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with...

UK publishes £2bn vision for engineering biology
Following extensive engagement with industry and stakeholders, the new "National Vision for Engineering Biology" lays out the government’s...

AstronauTx closes £48m Series A financing
The finanicing round of AstronauTx Ltd was led by the Novartis Venture Fund, with participation of MPM Capital, Brandon Capital, EQT Life Sciences,...

Oxford Biomedica acquires ABL Europe for €15m
Oxford Biomedica PLC, and Institut Mérieux have entered exclusive negotiations for the acquisition of ABL Europe Inc. This move is set to solidify...